Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for BioMed Research International, enter your email address in the box below.

Research Article
BioMed Research International
Volume 2015, Article ID 314651, 2 pages
http://dx.doi.org/10.1155/2015/314651
Corrigendum

Corrigendum to “Genetic Diagnosis of Charcot-Marie-Tooth Disease in a Population by Next-Generation Sequencing”

Helle Høyer,1,2,3 Geir J. Braathen,1,2,3 Øyvind L. Busk,1 Øystein L. Holla,1 Marit Svendsen,1 Hilde T. Hilmarsen,1 Linda Strand,1 Camilla F. Skjelbred,1 and Michael B. Russell2,3

1Section of Medical Genetics, Department of Laboratory Medicine, Telemark Hospital, 3710 Skien, Norway
2Head and Neck Research Group, Research Centre, Akershus University Hospital, Lørenskog, Norway
3Campus Akershus University Hospital, University of Oslo, Nordbyhagen, Norway

Received 8 September 2015; Accepted 21 September 2015

Copyright © 2015 Helle Høyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In Table and Supplemental Table of the published paper entitled “Genetic Diagnosis of Charcot-Marie-Tooth Disease in a Population by Next-Generation Sequencing” [1], we classified two variants as likely pathogenic. These two variants (NM_001126131.1:c.[1491G>C(;)2243G>C]), identified in the POLG gene, were carried by one patient (ID 62). As it was not possible to examine whether the two variants were in cis or trans, that is, situated on the same or different alleles, these two variants should have been reported as uncertain pathogenic variants.

This change also influences the Results, where the prevalence of identified variants is corrected to 8 likely and 17 uncertain pathogenic variants.

In Figure , the number of families with likely pathogenic variants is reduced to   (9%) and the number for families with uncertain pathogenic variants is increased to   (12%). And in Figure (b), the number of CMT2 families in the category “other point mutations” is reduced to   (21%) and the number of families with uncertain pathogenic variants is increased to   (15%). See corrected Figures 1 and 2(b).